Evidence map›Paper›PMID 26060072›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2015

T Cell Receptor Engineering and Analysis Using the Yeast Display Platform.

Sheena N Smith, Daniel T Harris, David M Kranz

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
6.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Engineering Proteins by Combining Deep Mutational Scanning and Yeast Display.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Tuning up T-cell receptors.Nature biotechnology · 2017
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sheena N SmithDepartment of Biochemistry, University of Illinois, 600 S. Matthews Ave., Urbana, IL, 61801, USA.
Daniel T Harris
David M Kranz
University of Illinois Urbana-Champaign · USUrbana University · US

Funding

Protein Expression and Peptide CoreP01CA097296 · NCI · UNIVERSITY OF CHICAGO · PI MEREDITH, STEPHEN C. · 2003 to 2012
$15.0M
Training Program in Chemistry-Interface with BiologyT32GM070421 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI HERGENROTHER, PAUL · 2005 to 2019
$5.4M
Engineering High-Affinity T Cell Receptors Against Cancer AntigensF30CA180723 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI HARRIS, DANIEL · 2013 to 2018
$275k
NCI NIH HHS F30 CA180723NCI NIH HHS P01 CA097296NIGMS NIH HHS T32 GM070421
6 · The paper itself

Abstract

The αβ heterodimeric T cell receptor (TCR) recognizes peptide antigens that are transported to the cell surface as a complex with a protein encoded by the major histocompatibility complex (MHC). T cells thus evolved a strategy to sense these intracellular antigens, and to respond either by eliminating the antigen-presenting cell (e.g., a virus-infected cell) or by secreting factors that recruit the immune system to the site of the antigen. The central role of the TCR in the binding of antigens as peptide-MHC (pepMHC) ligands has now been studied thoroughly. Interestingly, despite their exquisite sensitivity (e.g., T cell activation by as few as 1-3 pepMHC complexes on a single target cell), TCRs are known to have relatively low affinities for pepMHC, with K D values in the micromolar range. There has been interest in engineering the affinity of TCRs in order to use this class of molecules in ways similar to now done with antibodies. By doing so, it would be possible to harness the potential of TCRs as therapeutics against a much wider array of antigens that include essentially all intracellular targets. To engineer TCRs, and to analyze their binding features more rapidly, we have used a yeast display system as a platform. Expression and engineering of a single-chain form of the TCR, analogous to scFv fragments from antibodies, allow the TCR to be affinity matured with a variety of possible pepMHC ligands. In addition, the yeast display platform allows one to rapidly generate TCR variants with diverse binding affinities and to analyze specificity and affinity without the need for purification of soluble forms of the TCRs. The present chapter describes the methods for engineering and analyzing single-chain TCRs using yeast display.

Indexed as

AntigensBinding SitesHumansMajor Histocompatibility ComplexPeptide LibraryProtein BindingProtein EngineeringReceptors, Antigen, T-CellSaccharomyces cerevisiaeAntigensPeptide LibraryReceptors, Antigen, T-Cell

Identifiers

PMID26060072
PMCPMC5562502
OpenAlexW2337435106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.